Prakt. lékáren. 2022; 18(1): 14-20 [Med. praxi. 2021;18(5):316-321]

Depression in patients with cardiovascular disease - can be treated safely?

Eva Kitzlerová
Psychiatrická klinika 1. LF UK a VFN Praha

Depressive disorder is important risk factor for onset and development of cardiovascular diseases. It must be diagnosed and treated early and adequately. Now its evident that depressive symptoms in patients with cardiovascular diseases can be treated effectively and safety and that they can decrease burden of patients with other complications. The first choice of treatment are SSRI antidepressants, but SNRI or other modern antidepressants with specific mechanisms of action can be also used. During the treatment is necessary use the safety dosage of antidepressants, think of individual risk factors for QT prolongation and severe ventricular arrhythmias and monitoring of electrocardiogram or blood pressure regularly. Healthy lifestyle, food and sleep are integral parts of pathogenesis of depression and cardiovascular diseases.

Keywords: depression, cardiovascular diseases, safety treatment, antidepressants.

Published: March 14, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kitzlerová E. Depression in patients with cardiovascular disease - can be treated safely? Praktické lékárenství. 2022;18(1):14-20.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet, updated May 2017. Available at: http:// www.who.int/mediacentre/factsheets/fs317/en/.
    2. Walker ER, McGee RE, Druss BG. Mortality in mental disorreds and global disease burden implications: a systematic review and meta analysis. JAMA Psychiatry 2015; 72(4): 334-341. Go to original source... Go to PubMed...
    3. Gan Y, Gong Y, Tong X, et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort sudies. BMC Psychiatry. 2014; 14: 371. Go to original source... Go to PubMed...
    4. Whooley MA, Wong JM. Depression and Cardiovascular Disorders. Annu Rev Clin Psychol. 2013; 9: 327-354. Go to original source... Go to PubMed...
    5. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014; 129(12): 1350-1369. Go to original source... Go to PubMed...
    6. Doyle F, Mc Gee H, Conroy R, et al. Systematic review and individual patient data meta-analysis of sex diffrences in depression and prognosis in persons with myocardial infarction: a MINDMAPS Study. Psychosom Med 2015; 77(4): 419-428. Go to original source... Go to PubMed...
    7. Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P. Prognostic association of depression following myocardial infarctiion with mortality and cardiovascular events: a meta - anylsis of 25 years of research. Gen Hosp Psychiatry 2011; 33(3): 203-216. Go to original source... Go to PubMed...
    8. Kitzlerová E, Anders M. The role of some new factors in the pathophysiology of depression and cardiovascular disease: Overview of Recent Research. Neuroendocrinol Lett 2007; 28(6): 832-840. Go to PubMed...
    9. Vacarino V. The association between depression and coronary heart disease incidence. Drugs of Today 2000; 36(10): 715-724. Go to original source... Go to PubMed...
    10. de Hert M, Detraux J, Vancapfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 2018; 20: 31-39. Go to original source... Go to PubMed...
    11. Amare AT, Schubert KC, Klingler-Hoffmann M, Cohen-Woods S, Baume BT. The gentic overlap between modd disorders and cardiometabolic disease: a systematic review of genome wide and candidate gene studies.Transl Psychiatry 2017; 7(1): e1007. Go to original source... Go to PubMed...
    12. Moon E, Lee SH, Kim DH, Hwang B. Comparative study of heart rate variability in patients with schizophrenia, bipolar disorder, post-traumatic stress disorder or major depressive disorderd. Clin Psychopharmacol Neurosci 2013; 11(3): 137-143. Go to original source... Go to PubMed...
    13. Glassman AH, O'Connor CM, Califf RM, et al.; for the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-709. Go to original source... Go to PubMed...
    14. Taylor CB, Youngblood ME, Catellier D, et al.; for the ENRICHD Investigators. Effects of Antidepressant Medication on Morbidity and Mortality in Depressed Patients After Myocardial Infarction. Arch Gen Psychiatry 2005; 62: 792-798. Go to original source... Go to PubMed...
    15. Surtees PG, Wainwright NWJ, Luben R, Day NE, Khaw KE. Prospective cohort study of hostiliy and the risk of cardiovascular disease mortality. Int J Cardiology 2005; 100: 155-161. Go to original source... Go to PubMed...
    16. Todaro JF, Noc A, Niaura R, Spiro A, Ward KD, Roytberg A. Combined Effect of the Metabolit Syndrome and Hostility on the Incidence of Myocardial Infarction (The Normative Aging Study). Am J Cardiol 2005; 96: 221-226. Go to original source... Go to PubMed...
    17. Grabe HJ, Lange M, Wolff B, Volzke H, Lucht M, Freyberger HJ, John U, Cascorbi I. Mental and physical mistress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chornic disease burden. Molecular Psychiatry 2005; 10: 220-224. Go to original source... Go to PubMed...
    18. Cirimele V, Kintz P, Tracqui A, Mangin P. A fatal dothiepin overdose. Forensic Science International 1995; 76: 205-209. Go to original source... Go to PubMed...
    19. Montgomery SA, Baldwin D, Green M. Why do amitriptyline and dothiepin appear to be so dangerous in overdose? Acta Psychiatr. Scand. 1989; 80(suppl.354): 47-53. Go to original source... Go to PubMed...
    20. Pizzi C, Rutjes AW, Costa GM, Fontana F, et al. Meta-analysis of SSRIs in patients with depression and coronary heart disease. Am J Cardiol 2011; 107(7): 972-979. Go to original source... Go to PubMed...
    21. Prasitlumkum N, Cheungpasitporn W, Tokavanich N, et al. Antidepressants and Risk of Sudden Cardiac Death: A Network Meta-Analysis and Systematic Review. Med. Sci. 2021; 9: 26. https://doi.org/10.3390/medsci9020026. Go to original source... Go to PubMed...
    22. Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, Pilgrim T. Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. ESC Heart Failure 2020; 7: 3610-3620. Go to original source... Go to PubMed...
    23. Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs 2020. https://doi.org/10.1007/s40263-020-00763-z. Go to original source... Go to PubMed...
    24. Sauer WH, Berlin JA, Kimmel SE. SSRIs and myocardial infarction. Circulation 2001; 104: 1894-1898. Go to original source... Go to PubMed...
    25. Rasmusen SL, Overo KF, Tanghøj P. Cardiac safety of Citalopram: Prospective Trials and Retrospective analyses. J ClinPsychopharmacology, October 1999; 19(5): 407-415. Go to original source... Go to PubMed...
    26. Aronow WS, Shamliyan TA. Effects of antidepressants on QT interval in people with mental disorders. Arch Med Sci 2020; 16(4): 727-741. Go to original source... Go to PubMed...
    27. van den Brink, van Melle JP, Honig A et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial Infarction and depression - intervention Trial (MIND-IT). Am heart J 2002; 144(2): 219-225. Go to original source... Go to PubMed...
    28. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin. Drug Saf. 2015; 10.1517/14740338.2015.1046836. Go to original source... Go to PubMed...
    29. Baldwin DS, Chrones L, Florea I, Nielsen R, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology 2016; 30(3): 242-252. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.